Christine S Walsh

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. ncbi Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas
    Christine S Walsh
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Women s Cancer Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Clin Cancer Res 14:7645-51. 2008
  2. ncbi Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening
    Christine S Walsh
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gynecol Oncol 116:516-21. 2010
  3. ncbi ERCC5 is a novel biomarker of ovarian cancer prognosis
    Christine S Walsh
    Department of Obstetrics and Gynecology, Cedars Sinai Women s Cancer Research Institute, Samuel Oschin Comprehensive Cancer Institute, David Geffen School of Medicine, University of California at Los Angeles, CA 90048, USA
    J Clin Oncol 26:2952-8. 2008
  4. ncbi Molecular signatures of ovarian cancer: from detection to prognosis
    Christine S Walsh
    Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Mol Diagn Ther 14:13-22. 2010
  5. ncbi Contemporary progress in ovarian cancer screening
    Christine S Walsh
    Department of Obstetrics and Gynecology, University of California, Los Angeles, David Geffen School of Medicine at UCLA, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Suite 160W, Los Angeles, CA 90048, USA
    Curr Oncol Rep 9:485-93. 2007
  6. ncbi Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk
    Christine S Walsh
    Department of Obstetrics and Gynecology, Cedars Sinai Women s Cancer Research Institute, David Geffen School of Medicine at UCLA, 8700 Beverly Boulevard, Suite 290W, Los Angeles, CA 90048, USA
    Gynecol Oncol 104:660-4. 2007
  7. ncbi Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer
    Nicole D Fleming
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Women s Cancer Research Institute, Los Angeles, California 90048, USA
    Cancer 118:689-97. 2012
  8. ncbi CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer
    Nicole D Fleming
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Women s Cancer Research Institute, Los Angeles, CA 90048, USA
    Gynecol Oncol 121:249-52. 2011
  9. ncbi Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene
    Claudia I Muller
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Leuk Res 31:27-32. 2007
  10. ncbi Is older age a poor prognostic factor in stage I and II endometrioid endometrial adenocarcinoma?
    Nicole D Fleming
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Women s Cancer Research Institute, Los Angeles, CA 90048, USA
    Gynecol Oncol 120:189-92. 2011

Detail Information

Publications15

  1. ncbi Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas
    Christine S Walsh
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Women s Cancer Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Clin Cancer Res 14:7645-51. 2008
    ..The importance of the BRCA gene products in maintaining genomic stability led us to hypothesize that BRCA-associated and sporadic ovarian cancers would have distinctive genetic profiles despite similarities in histologic appearance...
  2. ncbi Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening
    Christine S Walsh
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gynecol Oncol 116:516-21. 2010
    ..e. synchronous endometrial and ovarian cancer). Our study aims to estimate the prevalence of LS in these two populations...
  3. ncbi ERCC5 is a novel biomarker of ovarian cancer prognosis
    Christine S Walsh
    Department of Obstetrics and Gynecology, Cedars Sinai Women s Cancer Research Institute, Samuel Oschin Comprehensive Cancer Institute, David Geffen School of Medicine, University of California at Los Angeles, CA 90048, USA
    J Clin Oncol 26:2952-8. 2008
    ..Gene expression analyses were performed through microarray experiments. Candidate genes were tested for independent effects on survival using Cox proportional hazards models, Kaplan-Meier survival curves, and the log-rank test...
  4. ncbi Molecular signatures of ovarian cancer: from detection to prognosis
    Christine S Walsh
    Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Mol Diagn Ther 14:13-22. 2010
    ..In this review, we discuss the current state of biomarker development for the early detection of ovarian cancer and explore the continuing challenges to realizing this goal...
  5. ncbi Contemporary progress in ovarian cancer screening
    Christine S Walsh
    Department of Obstetrics and Gynecology, University of California, Los Angeles, David Geffen School of Medicine at UCLA, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Suite 160W, Los Angeles, CA 90048, USA
    Curr Oncol Rep 9:485-93. 2007
    ..We review the current status and the challenges of ovarian cancer screening in the context of evidence-based principles that define a valuable cancer screening program...
  6. ncbi Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk
    Christine S Walsh
    Department of Obstetrics and Gynecology, Cedars Sinai Women s Cancer Research Institute, David Geffen School of Medicine at UCLA, 8700 Beverly Boulevard, Suite 290W, Los Angeles, CA 90048, USA
    Gynecol Oncol 104:660-4. 2007
    ..The objective of this study was to examine the association between SNP309 and sporadic endometrial cancer risk...
  7. ncbi Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer
    Nicole D Fleming
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Women s Cancer Research Institute, Los Angeles, California 90048, USA
    Cancer 118:689-97. 2012
    ..The objective of this study was to determine whether single-nucleotide polymorphisms (SNPs) in NER pathway genes could be markers of platinum response in ovarian cancer...
  8. ncbi CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer
    Nicole D Fleming
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Women s Cancer Research Institute, Los Angeles, CA 90048, USA
    Gynecol Oncol 121:249-52. 2011
    ..We hypothesized that a shorter time interval between CA125 elevation and SCS correlates with a higher likelihood of optimal resection among eligible patients...
  9. ncbi Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene
    Claudia I Muller
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Leuk Res 31:27-32. 2007
    ..Additionally, a previously unidentified PIK3CA pseudogene spanning exons 9-13 on chromosome 22 was discovered...
  10. ncbi Is older age a poor prognostic factor in stage I and II endometrioid endometrial adenocarcinoma?
    Nicole D Fleming
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Women s Cancer Research Institute, Los Angeles, CA 90048, USA
    Gynecol Oncol 120:189-92. 2011
    ..The purpose of this study is to assess if age is an independent poor prognostic factor in endometrioid histologies...
  11. ncbi FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias
    Jee Hoon Song
    Department of Medicine, UCLA Cedars Sinai Research Institute, 110 George Burns Drive, Davis 5016, Los Angeles, CA 90034, USA
    Leuk Res 32:1751-5. 2008
    ..All mutations affected the FBXW7 target interacting domain. These observations suggest that disruption of FBXW7 has a role in several forms of lymphocytic leukemias and not exclusively T-cell acute lymphocytic leukemia...
  12. ncbi Discovery of epigenetically masked tumor suppressor genes in endometrial cancer
    Noriyuki Takai
    Division of Hematology/Oncology, Cedars-Sinai Medical Center/University of California at Los Angeles School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Mol Cancer Res 3:261-9. 2005
    ..Our data suggest that C/ebpalpha and Tig1 function as tumor suppressor proteins in endometrial cancers and that their reexpression may be a therapeutic target...
  13. ncbi The prognostic significance of thrombocytosis in uterine papillary serous carcinomas
    Dimitry L Lerner
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, 8700 Beverly Blvd, Suite 160W, Los Angeles, CA 90048, USA
    Gynecol Oncol 104:91-4. 2007
    ..In light of the similarities between uterine papillary serous carcinomas (UPSC) and EOC, we sought to determine the incidence of thrombocytosis in UPSC and examine associations with clinico-pathologic features and survival...
  14. ncbi Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy
    Kristine R Penner
    Department of Obstetrics and Gynecology, Olive View UCLA Medical Center, Sylmar, CA 91342, USA
    Gynecol Oncol 124:542-8. 2012
    ..To identify clinical and pathologic predictors of response to progestin treatment in premenopausal women with complex atypical hyperplasia (CAH) and Grade 1 endometrial adenocarcinoma (Grade 1 EA)...
  15. ncbi Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
    Amanda Nickles Fader
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A 81, Cleveland, Ohio 44195, USA
    Gynecol Oncol 112:558-62. 2009
    ..To determine recurrence patterns and survival outcomes of stage II uterine papillary serous carcinoma (UPSC) patients treated by various modalities with an emphasis on carboplatin/paclitaxel-based chemotherapy (CT)+/-radiotherapy (RT)...